Eliksa Therapeutics
PrivateLast Round
Strategic
Oct 29, 2025
Company Overview
Eliksa Therapeutics operates in Healthcare & Life Sciences and is based in Doylestown, Pennsylvania. Its latest recorded funding round was a Strategic round in October 2025.
Eliksa Therapeutics is a biotechnology company that develops novel medicines for a range of debilitating diseases using the regenerative properties of amniotic fluid and amniotic membrane.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eliksa Therapeutics Comparables
Compare Eliksa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nova Anchora | 73% | |
| Castle Creek Biosciences | 71% | |
| RHEACELL GmbH & Co. KG | 71% |
For institutional investors. Book with your work email.
Eliksa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Oct 29, 2025 | ||||
| Seed | Jul 19, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Eliksa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Benjamin Franklin Technology Partners | Seed |
| Militia Hill Ventures | Seed |
| BioAdvance Capital | Seed |
| DEBRA Research gGmbH | Strategic |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 1, 2026
Monthly visitors increased 141% MoM.
For institutional investors. Book with your work email.
Eliksa Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Eliksa Therapeutics's valuation, stock price, and market status.
Is Eliksa Therapeutics a public or private company?
Eliksa Therapeutics is a private company.
What is the current stock price of Eliksa Therapeutics?
Eliksa Therapeutics is a private company, so its shares have no public market price. Caplight tracks Eliksa Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Eliksa Therapeutics worth (valuation)?
Valuation information for Eliksa Therapeutics is not publicly available.
Can I buy Eliksa Therapeutics stock?
Eliksa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Eliksa Therapeutics's last funding round?
Eliksa Therapeutics's most recent funding round was Strategic on October 29, 2025.
Who are the main investors in Eliksa Therapeutics?
Key investors in Eliksa Therapeutics include DEBRA Research gGmbH.
Will Eliksa Therapeutics IPO soon?
No public IPO plans have been announced for Eliksa Therapeutics.
How can I track Eliksa Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Eliksa Therapeutics's shares on secondary markets.